Immunotoxins targeting B cell malignancy-progress and problems with immunogenicity

Daniel A. Vallera; Robert J. Kreitman

doi:10.3390/biomedicines7010001

Immunotoxins targeting B cell malignancy-progress and problems with immunogenicity

Daniel A. Vallera, Robert J. Kreitman

Radiation Oncology

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues to be immunogenicity exemplified by the anti-toxin response of the treated patient. Since some of our most effective toxins are bacterial in nature and bacterial proteins are highly immunogenic, this review describes some efforts to address this pressing issue.

Original language	English (US)
Article number	1
Journal	Biomedicines
Volume	7
Issue number	1
DOIs	https://doi.org/10.3390/biomedicines7010001
State	Published - Mar 1 2019

Bibliographical note

Funding Information:
This work was supported in part by the U.S. Public Health Service Grant R01-CA36725 awarded by the NCI and the NIAID, DHHS, the Lion Fund, the Randy Shaver Foundation, and a CETI translational award from the University of Minnesota Masonic Cancer Center

Publisher Copyright:
© 2019 by the authors.

Keywords

B-cell malignancies
CD19
CD22
Chemo-immunosuppression
Deimmunized
Diphtheria toxin
Immunogenicity
Immunotoxin
Pseudomonas exotoxin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.3390/biomedicines7010001

OpenUrl availability

Full text

Cite this

@article{b1085acf26e84abda01513c0ed5183ba,

title = "Immunotoxins targeting B cell malignancy-progress and problems with immunogenicity",

abstract = "Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues to be immunogenicity exemplified by the anti-toxin response of the treated patient. Since some of our most effective toxins are bacterial in nature and bacterial proteins are highly immunogenic, this review describes some efforts to address this pressing issue.",

keywords = "B-cell malignancies, CD19, CD22, Chemo-immunosuppression, Deimmunized, Diphtheria toxin, Immunogenicity, Immunotoxin, Pseudomonas exotoxin",

author = "Vallera, {Daniel A.} and Kreitman, {Robert J.}",

note = "Funding Information: This work was supported in part by the U.S. Public Health Service Grant R01-CA36725 awarded by the NCI and the NIAID, DHHS, the Lion Fund, the Randy Shaver Foundation, and a CETI translational award from the University of Minnesota Masonic Cancer Center Publisher Copyright: {\textcopyright} 2019 by the authors.",

year = "2019",

month = mar,

day = "1",

doi = "10.3390/biomedicines7010001",

language = "English (US)",

volume = "7",

journal = "Biomedicines",

issn = "2227-9059",

publisher = "MDPI AG",

number = "1",

}

TY - JOUR

T1 - Immunotoxins targeting B cell malignancy-progress and problems with immunogenicity

AU - Vallera, Daniel A.

AU - Kreitman, Robert J.

N1 - Funding Information: This work was supported in part by the U.S. Public Health Service Grant R01-CA36725 awarded by the NCI and the NIAID, DHHS, the Lion Fund, the Randy Shaver Foundation, and a CETI translational award from the University of Minnesota Masonic Cancer Center Publisher Copyright: © 2019 by the authors.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues to be immunogenicity exemplified by the anti-toxin response of the treated patient. Since some of our most effective toxins are bacterial in nature and bacterial proteins are highly immunogenic, this review describes some efforts to address this pressing issue.

AB - Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues to be immunogenicity exemplified by the anti-toxin response of the treated patient. Since some of our most effective toxins are bacterial in nature and bacterial proteins are highly immunogenic, this review describes some efforts to address this pressing issue.

KW - B-cell malignancies

KW - CD19

KW - CD22

KW - Chemo-immunosuppression

KW - Deimmunized

KW - Diphtheria toxin

KW - Immunogenicity

KW - Immunotoxin

KW - Pseudomonas exotoxin

UR - http://www.scopus.com/inward/record.url?scp=85063572342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063572342&partnerID=8YFLogxK

U2 - 10.3390/biomedicines7010001

DO - 10.3390/biomedicines7010001

M3 - Review article

C2 - 30577664

AN - SCOPUS:85063572342

SN - 2227-9059

VL - 7

JO - Biomedicines

JF - Biomedicines

IS - 1

M1 - 1

ER -

Immunotoxins targeting B cell malignancy-progress and problems with immunogenicity

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this